Zealand Pharma (ZEAL.CO) Stock Analysis & AI Equity Report
Zealand Pharma (ZEAL.CO) overview
Zealand Pharma (ZEAL.CO) stock analysis and AI equity research. For the latest completed financial year, 2025, Zealand Pharma reported revenue of DKK 9,215m and operating profit of DKK 7,156m; the year-end share price was 466.40 DKK and market capitalisation was DKK 32,882m. Zealand Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Zealand Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-06. Data will be refreshed during report generation.
About Zealand Pharma
Zealand Pharma A/S is a biotechnology company focused on the discovery, design and development of peptide-based and small-molecule medicines. Its pipeline targets obesity and broader metabolic health, while also addressing rare diseases such as congenital hyperinsulinism and short bowel syndrome, and selected chronic inflammatory diseases. The company also pursues development and commercialization partnerships.
Generate the Zealand Pharma report
Zealand Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Zealand Pharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.